January 2022 - BioMedWire (BMW)

MondayJan 31, 2022 1:05 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics. Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously missing. Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow. Enrollment for the study begins early this year (https://ibn.fm/XTXAe). “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after…

MondayJan 31, 2022 12:45 pm

Microsoft Corp. (NASDAQ: MSFT) Partners with Major Organizations to Promote AI Innovation in Healthcare

Microsoft (NASDAQ: MSFT) has formed an alliance, the Artificial Intelligence Industry Innovation Coalition (“AI3C”), with major health and life science organizations in the United States. The tech giant’s aim is to create and track new artificial intelligence innovations as the use of AI in healthcare grows. These organizations include the University of Virginia, the University of California-San Diego, Providence, Plug and Play, Novant Health, Intermountain Healthcare, Duke Health, Cleveland Clinic and the Brookings Institution. A survey conducted by Optum revealed that a significant number of healthcare executives plan to adopt or have adopted AI strategies. Senior executives from these organizations…

FridayJan 28, 2022 12:44 pm

Study Finds That Patients with Childhood Trauma May Benefit from PTSD Treatment

A new study has found that adults who were mistreated or abused as children and suffer from PTSD as a result of this may benefit from cognitive behavioral therapy. The study was carried out by a team of 15 therapists led by Danielle Oprel, a clinical psychologist, and Chris Hoeber, a PhD candidate and researcher. The researchers are hopeful about the perspective the study’s findings provide to individuals with serious PTSD symptoms. Hoeber’s objective was to determine which form of prolonged exposure therapy was the most effective for this particular group. The study was comprised of 149 patients, most of…

FridayJan 28, 2022 11:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO

NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification NMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch Limited MySugarWatch Limited aims to market devices via subscription-based diabetes coaching and management service Nemaura Medical (NASDAQ: NMRD), a medical technology company developing affordable non-invasive wearable diagnostic devices and digital tools for chronic disease management, recently appointed Dr. Arash Ghadar as Chief Operating Officer (https://ibn.fm/tj1TZ). Dr. Ghadar brings decades of UK-based technical…

ThursdayJan 27, 2022 12:12 pm

Brain Cancer Affecting Young Military Veterans in the US

PTSD and traumatic brain injuries are the primary indications affecting veterans, with almost 500,000 troops living with these diseases. However, thousands more have also been diagnosed as having illnesses that may be connected to toxic waste and environmental hazards. Hundreds of veterans are fighting glioblastoma, with some succumbing to the fatal disease. Glioblastoma is a common and aggressive type of cancer affecting the brain. It occurs in an individual’s spinal cord or brain. Research done on veterans and military personnel to determine why glioblastoma rates are higher in the active-duty population in comparison to the population in general haven’t produced…

ThursdayJan 27, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health treatment” Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://ibn.fm/3ZGGE). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE American: CYBN) has been working toward since the company started: a strategic psychedelics to therapeutics model that will transform the mental health space. “If you haven't heard about psychedelics being used as a treatment…

WednesdayJan 26, 2022 1:19 pm

Experts Forecast Increase in Brain Cancer in the US

Brain tumors are noncancerous or cancerous masses or growths of abnormal cells in the brain. Brain cancer usually originates in the central nervous system, which is made up of the spinal cord and the brain. Over the last 10 years, this serious and often debilitating ailment has been discussed and well documented, despite it not being as common as other types of cancer. Research has shown that brain cancer is more common in men, with epidemiologists from GlobalData predicting that over one-half of all newly diagnosed cases in the United States being individuals aged 60 and above. They expect this…

WednesdayJan 26, 2022 12:15 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market

The global cannabinoid-based pharmaceuticals market is projected to be valued at $50 billion by 2029 InMed is leading the industry, laying down the foundation in manufacturing and clinical development of rare cannabinoids It is shedding light on the potential of rare cannabinoids and laying the groundwork on how to tap into the industry’s growth It is projected that by 2025, the global cannabis market will be valued at around $146 billion, up from just $20.47 billion in 2020. This sector is experiencing tremendous growth, particularly considering that there are over one hundred known cannabinoids, including rare ones that are quickly…

TuesdayJan 25, 2022 11:38 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement

CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”) The approval is the first from a European Ethics Committee The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and Switzerland CNS recently closed an $11.5 million private placement It intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D programs, and for general corporate purposes Clinical stage biotechnology company CNS Pharmaceuticals (NASDAQ: CNSP) is celebrating…

TuesdayJan 25, 2022 10:37 am

Experts Discuss Addiction and How to Support Individuals Battling the Disease

Researchers at the University of Virginia are conducting new research that will assist in identifying and helping individuals who are struggling with addiction, through the institution’s Center for Leading Edge Addiction Research (“CLEAR”), which develops addiction treatments. Data from the National Center for Drug Abuse Statistics shows that between 2009 and 2019, the number of overdose-related fatalities recorded for individuals aged 15 to 24 grew to 4,777 from less than 3,400 deaths. This increase has been linked to opioid overdoses, some of which are caused by fentanyl laced cocaine. Studies by the Addiction Center have found that in comparison to…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: January 2022

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year

Microsoft Corp. (NASDAQ: MSFT) Partners with Major Organizations to Promote AI Innovation in Healthcare

Study Finds That Patients with Childhood Trauma May Benefit from PTSD Treatment

Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO

Brain Cancer Affecting Young Military Veterans in the US

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Experts Forecast Increase in Brain Cancer in the US

InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement

Experts Discuss Addiction and How to Support Individuals Battling the Disease

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search